ProBiotix Health, the life sciences business developing probiotics to support cardiometabolic health, has announced a commercial partnership with Australia-based Wellizen.
Wellizen is an innovation-driven wellness consumer brand focused on health solutions in nutrition, microbiome, and lifestyle wellness. It has successfully established its consumer brand, THERONOMIC, as a market leader in the precision biotic supplement space.
ProBiotix will supply LPLDL for local manufacturing of a new innovative dietary supplement capsule product targeting cardiometabolic health: Tri-Biotic Cardi-Flo, introduced under the THERONOMIC brand.
The commercial rollout will take place in October this year, with an initial launch in Singapore through Wellizen's direct retail consumer e-commerce platform, followed by a late October direct-to-consumer launch in Australia.
Additional market entries across New Zealand, Southeast Asia and other Asian markets are planned for the coming months as part of a phased regional expansion strategy.
The nutraceutical segment addressing cardiometabolic health is experiencing strong growth across all target regions, driven by rising lifestyle-related health concerns and demand for clinically supported, science-based preventive product solutions.
"The use of our clinically proven LPLDL by Wellizen to complement their existing THERONOMIC consumer product range marks a significant step for ProBiotix. It further validates the increasing application of our innovative technology to target those suffering from high cholesterol, and we are very excited about its future sales potential,” said Steen Andersen, CEO of ProBiotix.
"High cholesterol affects an estimated 30 to 48 percent of adults in Southeast Asia, around 30 percent in Australia, and nearly one-third of adults across the Middle East, representing a major and fast-growing cardiometabolic health challenge globally.”
Julie Chen, Head of R&D of THERONOMIC, was also excited to launch THERONOMIC Cardi-Flo as part of the ongoing mission to deliver science-backed solutions that address health at its root through the gut.
"This product showcases our innovative Tribiotic platform and features LPLDL, a clinically studied probiotic strain with proven benefits for cardiometabolic health,” said.
“Our partnership with ProBiotix reflects a shared commitment to advancing microbiome science, and we are confident Cardi-Flo will bring meaningful impact to consumers seeking natural, evidence-based support for heart health."
More global news here
